Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.
- Author:
Edward Wolfgang LEE
1
;
Sarah KHAN
Author Information
- Publication Type:Review
- Keywords: Hepatocellular carcinoma; Transarterial chemoembolization; Bland embolization; Selective internal radiation therapy; Yttrium-90; Radioembolization
- MeSH: Carcinoma, Hepatocellular*; Embolization, Therapeutic*; Humans; Yttrium
- From:Clinical and Molecular Hepatology 2017;23(4):265-272
- CountryRepublic of Korea
- Language:English
- Abstract: Management of hepatocellular carcinoma (HCC) can be maximized with the utilization of multiple treatment modalities including transplant, surgical resection and locoregional therapies including ablative therapies and transarterial embolotherapies. Although transplant and surgical resection offer the best clinical outcomes, a limited number of patients are amenable to these surgical treatment options due to the advanced disease at presentation. Transarterial embolotherapies including conventional transarterial chemoembolization (cTACE), bland transarterial embolization (TAE), drug-eluting beads transarterial chemoembolization (DEB-TACE) and selective internal radiation therapy (SIRT) with Yttrium 90 (⁹⁰Y) have played an increasingly important role for these patients with unresectable HCC. With a better understanding of different transarterial embolotherapies, more personalized and precise treatment should be implemented for these patients with unresectable HCC. In this review, the updated evidence on the current role of each embolotherapy in the treatment of HCC is summarized.
